Last reviewed 2026-04-20 · How we verify

Cyclophosphamide Conditioning

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pyrexia
• Infection
• Neutropenia
• Diarrhoea
• Anaemia
• Headache
• Grades 3-5 Cardiac Disorders
• Fatigue
• Pneumonia
• Nausea
• Hypotension
• Sinus tachycardia

Key clinical trials

• Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
• Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
• Study of LYL314 in Aggressive Large B-Cell Lymphoma (PHASE1, PHASE2)
• MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
• Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
• Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.